MorphoSys Completes Sale of AbD Serotec to Bio-Rad
News Jan 11, 2013
MorphoSys AG has announced that the sale of its research and diagnostic antibody segment AbD Serotec to Bio-Rad Laboratories, Inc. has been completed.
All assets and liabilities of the AbD Serotec segment of MorphoSys AG as well as all shares of the subsidiaries MorphoSys UK Ltd., MorphoSys AbD GmbH and MorphoSys US, Inc. have been transferred to Bio-Rad.
"We are delighted to have reached the closing of the transaction just a few weeks after the announcement was made. With the divestment of AbD Serotec completed, MorphoSys can devote 100% of its attention to building value in its core therapeutics business," commented Jens Holstein, Chief Financial Officer of MorphoSys AG.
Consuming Sugary Drinks During Pregnancy May Increase Asthma Risk in Mid-ChildhoodNews
Children between the ages of 7 and 9 may be at greater risk for developing asthma if they consumed high amounts of fructose in early childhood or their mothers drank a lot of sugar-sweetened beverages while pregnant, according to new research.READ MORE
An Anti-Aging Protein Could Be Targeted to Rejuvenate Immune CellsNews
A new study explains what happens when the immune system ages, and has identified two potential new drug targets which could help postpone the development of age-related diseases.READ MORE